Utilization trends for GLP1s (glucagon-like peptides, used to treat diabetes and sometimes obesity) will continue to increase in 2024, adding cost to the system and pressure on payers and employers to cover treatments.

Find out more.

See how rule of three’s strategic services can support you and your healthcare team.

How We Work